SALE-based law firm, Slater Heelis, has closed a round of investment for pharmaceutical developer, Blueberry Therapeutics, helping the company to secure $1.75 million of funding.
The capital will allow Blueberry to progress two anti-fungal programmes – which represent some of the company’s most advanced research – to clinical trial.
The programmes have been in development for two years and the investment will now enable Blueberry to move its programs to clinical testing, with the aim of eventually gaining approval for two innovative new medicines that will significantly improve cure rates and treatment times for fungal infections.
Simon Wallwork, partner at Slater Heelis and key adviser on the investment, said: “Blueberry Therapeutics continues to develop an impressive range of pharmaceutical solutions and I’m confident that this funding will enable it to create new products that will lead to positive outcomes for patients and treatment providers.”
Blueberry Therapeutics is a pharmaceutical company specialising in the development of innovative therapies to treat diseases where infection and inflammation are major factors.
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here